ZYDUSLIFE

has received final approval from the USFDA to manufacture 60 mg Apalutamide tablets, which are used for treating metastatic castration-sensitive prostate cancer. This drug, known for its significant sales, highlights the ongoing advancements in cancer treatment options. Approval Details:- Ltd will produce the Apalutamide tablets at their facility in Ahmedabad. The approval marks a significant step in expanding the availability of this treatment for prostate cancer patients.